

February 17, 2022

Akira Sasa, Representative Director EPS Corporation  
Kenji Sakuma, Representative Director EP-CRSU Co., Ltd.  
Akira Sasa, Representative Director EP Croit Co., Ltd.

## **Announcement on Reorganization of CRO Business**

EPS Corporation, EP-CRSU Co., Ltd., and EP Croit Co., Ltd. are pleased to announce that the three companies will absorb and merge, and integrate their businesses. EPS Corporation will be the surviving company.

### **1. Purpose of the Reorganization**

This restructuring, one of the initiatives of “New EPS”, follows a management buyout (MBO) that was completed last year, when the EPS Group celebrated its 30th anniversary.

The three companies to be restructured have been developing their businesses while taking advantage of each company's unique characteristics and have thus established their respective business foundations. However, the business environment surrounding CROs has recently undergone major changes.

In the field of real-world evidence, utilization of daily clinical data such as receipts, electronic medical records, PHRs (Personal Health Records) and patient registries are expanding, in addition to post-marketing surveillance and pharmacovigilance as an extension of drug development. In the field of clinical trials, the widespread use of DCTs (Decentralized Clinical Trials) is beginning to become a reality in Japan on the back of the COVID-19 pandemic. Furthermore, the use of patient registry data as control arm data for clinical trials is now at the practical stage, and the barriers between clinical and real-world trials are expected to become lower in the future.

On the other hand, under the healthcare policy in Japan, the importance of measures regarding pre-symptomatic illnesses and disease prevention is increasing along with the progress of treatments, due to the backdrop of the continual increase in national health care costs. As such, there is an increase in opportunities for business such as cooperating with local governments to encourage medical checkups.

In addressing the above-mentioned issues, one constant is the need for new technologies such as ICT and AI. The purpose of this reorganization is to promote the creation of solutions that meet the needs of the new era by bringing together the experience and knowledge dispersed among the three EPS Group branches: EPS Corporation, which focuses on clinical development support services, EP-CRSU Co., Ltd., which focuses on services for academia, and EP Croit Co., Ltd., which has solid IT technology.

Now, after the MBO, the EPS Group will rekindle the spirit and vitality of its founding and contribute to the further development of the health industry by boldly challenging new fields.



## 2. Effective Date of the Reorganization (Tentative)

(1) Absorption-Type Merger of EP-CRSU Co., Ltd. by EPS Corporation

Friday, April 1, 2022

(2) Absorption-Type Merger of EP Croit Co., Ltd. by EPS Corporation

Friday, July 1, 2022

## 3. Outline of the Company Structure Post-reorganization

	Surviving Company	Dissolving Company	Dissolving Company
Name	EPS Corporation	EP-CRSU Co., Ltd.	EP Croit Co., Ltd.
Location of head office	2-23 Shimomiyabicho, Shinjuku-ku, Tokyo, Japan	6-29 Shin-ogawamachi, Shinjuku-ku, Tokyo, Japan	6-29 Shin-ogawamachi, Shinjuku-ku, Tokyo, Japan
Representative	Akira Sasa, Representative Director	Kenji Sakuma, Representative Director	Akira Sasa, Representative Director
Business	Clinical Development, Post Marketing Surveillance and Pharmacovigilance	Clinical Research, Investigator-initiated Clinical Trials and Patient Registry	Clinical Development, Post Marketing Surveillance and Pharmacovigilance
Employees*	2,328	388	557
Capital	100 million yen	100 million yen	90 million yen
Principal Shareholder	EPS Holdings, Inc. (100%)	EPS Holdings, Inc. (100%)	EPS Corporation (100%)

\*January 2022

### For Inquiries

Public Relations Officer, General Affairs Office, Management Center, EPS Corporation

E-mail: [pri-epskoho@eps.co.jp](mailto:pri-epskoho@eps.co.jp)